Danaher (NYSE:DHR) Price Target Cut to $320.00

Danaher (NYSE:DHRGet Rating) had its target price reduced by stock analysts at Cowen from $340.00 to $320.00 in a report issued on Wednesday, The Fly reports. Cowen’s target price points to a potential upside of 17.83% from the stock’s current price.

Several other research analysts have also issued reports on DHR. Robert W. Baird dropped their price objective on Danaher from $321.00 to $309.00 in a research note on Wednesday. Benchmark cut Danaher from a “buy” rating to a “hold” rating and set a $325.00 price target on the stock. in a report on Monday, October 24th. StockNews.com upgraded Danaher from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Barclays raised their price target on Danaher from $277.00 to $290.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their target price on Danaher from $350.00 to $315.00 and set an “overweight” rating on the stock in a report on Friday, October 21st. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $310.29.

Danaher Stock Down 2.0 %

Shares of Danaher stock opened at $271.58 on Wednesday. Danaher has a 12-month low of $233.71 and a 12-month high of $303.82. The company has a quick ratio of 1.38, a current ratio of 1.78 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $197.70 billion, a P/E ratio of 30.01, a PEG ratio of 2.23 and a beta of 0.82. The stock has a 50 day moving average price of $266.13 and a two-hundred day moving average price of $268.98.

Danaher (NYSE:DHRGet Rating) last posted its quarterly earnings data on Tuesday, January 24th. The conglomerate reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.42. Danaher had a return on equity of 18.33% and a net margin of 21.65%. The company had revenue of $8.37 billion during the quarter, compared to analysts’ expectations of $7.90 billion. During the same period in the prior year, the business earned $2.69 earnings per share. Danaher’s revenue for the quarter was up 2.7% compared to the same quarter last year. Equities analysts expect that Danaher will post 10.55 earnings per share for the current year.

Insider Transactions at Danaher

In related news, EVP Jennifer Honeycutt sold 8,211 shares of the business’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $265.00, for a total value of $2,175,915.00. Following the completion of the sale, the executive vice president now directly owns 7,162 shares in the company, valued at approximately $1,897,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Jennifer Honeycutt sold 8,211 shares of the business’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $265.00, for a total value of $2,175,915.00. Following the completion of the sale, the executive vice president now directly owns 7,162 shares in the company, valued at approximately $1,897,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Matthew Mcgrew sold 18,935 shares of Danaher stock in a transaction on Friday, November 11th. The shares were sold at an average price of $274.72, for a total value of $5,201,823.20. Following the completion of the transaction, the chief financial officer now directly owns 29,634 shares of the company’s stock, valued at $8,141,052.48. The disclosure for this sale can be found here. In the last three months, insiders sold 38,538 shares of company stock worth $10,424,284. 11.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Danaher

A number of institutional investors have recently modified their holdings of DHR. Bishop Rock Capital L.P. raised its holdings in shares of Danaher by 13,959.3% during the 2nd quarter. Bishop Rock Capital L.P. now owns 3,955,166 shares of the conglomerate’s stock worth $15,601,000 after buying an additional 3,927,034 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Danaher by 515.0% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,348,688 shares of the conglomerate’s stock worth $606,643,000 after purchasing an additional 1,966,793 shares in the last quarter. Vanguard Group Inc. increased its holdings in Danaher by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 53,690,131 shares of the conglomerate’s stock worth $13,867,623,000 after purchasing an additional 995,501 shares in the last quarter. Castleview Partners LLC increased its holdings in Danaher by 23,726.6% in the 2nd quarter. Castleview Partners LLC now owns 791,996 shares of the conglomerate’s stock worth $3,124,000 after purchasing an additional 788,672 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec increased its holdings in Danaher by 70.1% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,376,545 shares of the conglomerate’s stock worth $348,982,000 after purchasing an additional 567,259 shares in the last quarter. Institutional investors and hedge funds own 77.26% of the company’s stock.

Danaher Company Profile

(Get Rating)

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines.

Featured Articles

The Fly logo

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.